

## Special Issue

# Prostate Cancer Progression

### Message from the Guest Editor

Prostate cancer is one of the most prevalent malignancies. While most cases are diagnosed at a localized stage, a considerable number of patients with intermediate or high-risk localized, locally advanced or metastatic cancer die from the disease each year. Although therapeutic advances have been introduced in the field of metastatic PC, androgen deprivation therapy remains the leading therapeutic backbone for metastatic PC. However, most patients develop castration resistance. The exact mechanisms driving the progression from androgen-dependent PC to castration-resistant prostate cancer are not completely understood. The treatment landscape of metastatic CRPC has substantially improved due to the availability of different agents. However, fast tumor progression, cross-resistance, the use of these substances in earlier stages of the disease, and patient-related factors should be taken into account when assessing which is the optimal treatment sequencing in the setting of mCRPC. This Issue aims, to better understand the biological mechanisms of tumor progression and, to elucidate recent clinical developments in the treatment of both localized and metastatic disease.

---

### Guest Editor

Dr. Isabel Heidegger-Pircher

Department of Urology, Medical University Innsbruck, 6020 Innsbruck, Austria

---

### Deadline for manuscript submissions

closed (25 October 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/124452](https://mdpi.com/si/124452)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)